Argyropoulos, Kimon V. http://orcid.org/0000-0003-1510-5887
Pulitzer, Melissa
Maura, Francesco http://orcid.org/0000-0002-5017-1620
Mohanty, Abhinita
Mondello, Patrizia http://orcid.org/0000-0002-0355-3757
Horwitz, Steven M.
Myskowski, Patricia
Moskowitz, Alison
Dogan, Ahmet http://orcid.org/0000-0001-6576-5256
Querfeld, Christiane
Rapaport, Franck
Siakantaris, Marina
Louis, Peter C.
Galasso, Natasha
van den Brink, Marcel R. M.
Palomba, M. Lia http://orcid.org/0000-0001-5099-9156
Article History
Received: 5 January 2020
Revised: 22 July 2020
Accepted: 17 September 2020
First Online: 9 November 2020
Conflict of interest
: S.M.H. is a consultant for Astex, Celgene, Affimed, Infinity/Verastem, Millennium/Takeda and Merck. Research grants include Corvus, Celgene, Infinity/Verastem, Millennium/Takeda, Seattle Genetics, Forty-Seven, Aileron, ADCT Therapeutics, Trillium, Daichii, Portola. A.D. has received personal fees from Roche, Corvus Pharmaceuticals, Physicians’ Education Resource, Seattle Genetics, Peerview Institute, Oncology Specialty Group, Pharmacyclics, Celgene, Novartis, Takeda and research grants from National Cancer Institute and Roche. A.M. has received research support from Seattle Genetics, Merck, Bristol-Myers Squibb, Incyte. She has received honorarium from Kyowa Hakko Kirin Pharma, Miragen Therapeutics, Takeda Pharmaceuticals, ADC Therapeutics, Seattle Genetics, Cell Medica, Bristol-Myers Squibb, Erytech Pharma. C.Q. is a Steering Committee member of Miragen, is in the Advisory Board of Helsinn/Actelion, Bioniz, Trillium, Kyowa Kirin, Medivir and Mallinckrodt; and receives research funding from Celgene. M.R.M.v.B. has received research support from Seres Therapeutics; has consulted, received honorarium from or participated in advisory boards for Seres Therapeutics, Flagship Ventures, Novartis, Evelo, Jazz Pharmaceuticals, Therakos, Amgen, Magenta Therapeutics, Merck & Co, Inc., Acute Leukemia Forum (ALF), and DKMS Medical Council (Board); has IP Licensing with Seres Therapeutics, Juno Therapeutics, and stock options from Smart Immune. M.L.P. is a consultant for Merck and Pharmacyclics.